Black Rock Inc. Mi Nk Therapeutics, Inc. Transaction History

Black Rock Inc.

$4.35 Trillion
Q2 2024

A detailed history of Black Rock Inc. transactions in Mi Nk Therapeutics, Inc. stock. As of the latest transaction made, Black Rock Inc. holds 87,196 shares of INKT stock, worth $45,341. This represents 0.0% of its overall portfolio holdings.

Number of Shares

87,196

Previous 76,148 14.51%

Holding current value

$45,341

Previous $69,000 18.84%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	BUY	$0.87 - $1.56 $9,611 - $17,234	11,048 Added 14.51%	87,196 $82,000
Q1 2024 May 10, 2024	SELL	$0.84 - $1.12 $259 - $346	-309 Reduced 0.4%	76,148 $69,000
Q4 2023 Feb 13, 2024	SELL	$0.88 - $1.21 $3,556 - $4,890	-4,042 Reduced 5.02%	76,457 $81,000
Q3 2023 Nov 13, 2023	SELL	$1.1 - $2.09 $1,683 - $3,197	-1,530 Reduced 1.87%	80,499 $88,000
Q2 2023 Aug 11, 2023	BUY	$0.89 - $3.33 $63,343 - $237,006	71,173 Added 655.61%	82,029 $172,000
Q1 2023 May 12, 2023	BUY	$1.9 - $2.48 $672 - $877	354 Added 3.37%	10,856 $20,000
Q4 2022 Feb 13, 2023	BUY	$1.89 - $3.16 $939 - $1,570	497 Added 4.97%	10,502 $27,000
Q3 2022 Nov 14, 2022	BUY	$1.19 - $3.4 $4,005 - $11,444	3,366 Added 50.7%	10,005 $21,000
Q2 2022 Aug 12, 2022	SELL	$1.25 - $3.25 $13,756 - $35,766	-11,005 Reduced 62.37%	6,639 $10,000
Q1 2022 May 12, 2022	BUY	$2.2 - $4.75 $15,939 - $34,413	7,245 Added 69.67%	17,644 $40,000
Q4 2021 Feb 10, 2022	BUY	$4.12 - $20.03 $42,843 - $208,291	10,399 New	10,399 $46,000

Others Institutions Holding INKT

# of Institutions

Shares Held

848K

Call Options Held

Put Options Held

View Full List

About MiNK Therapeutics, Inc.

Ticker INKT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 33,775,100
Market Cap $17.6M
Description
MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy...

More about INKT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

News

Stay updated on Black Rock Inc. with notifications on news.

Account